News Adagene Inc.

Equities

ADAG

US0053291078

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2.55 ^USD	-0.78%		+14.35%	+32.03%

Mar. 29	Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 29	Adagene Inc. Announces Board Changes	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adagene : Entry into Sales Agreement - Form 6-K	Mar. 29	PU
Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update	Mar. 29	GL
Adagene Inc. Announces Board Changes	Mar. 29	CI
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board	Mar. 07	GL
Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board	Mar. 07	CI
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	Feb. 27	GL
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	Feb. 27	AQ
ADRs Close Higher, Ambow Education Holding Ltd. Climbs 117.4%	Feb. 16	DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Feb. 09	MT
Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination	Feb. 09	MT
Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody	Feb. 09	CI
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	Feb. 09	GL
ADRs End Higher; The9 Climbs 16%	Jan. 19	DJ
Adagene Reports Positive Data on Colorectal Cancer Treatment Combination	Jan. 17	MT
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	Jan. 16	GL
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	Jan. 16	AQ
Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium	Jan. 16	CI
ADRs End Lower; Aslan Pharmaceuticals Declines 38%	Jan. 16	DJ
ADRs Slump, Grifols S.A. Declines 14.0%	Jan. 11	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Adagene Inc.

Equities

ADAG

US0053291078

Summary

Filters